Free Trial
NASDAQ:VIR

Vir Biotechnology Q2 2025 Earnings Report

Vir Biotechnology logo
$5.03 -0.04 (-0.79%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.17 +0.14 (+2.86%)
As of 08/1/2025 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology EPS Results

Actual EPS
N/A
Consensus EPS
-$0.83
Beat/Miss
N/A
One Year Ago EPS
N/A

Vir Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.38 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vir Biotechnology Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Vir Biotechnology Earnings Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Vir Biotechnology: Hep B And Cancer Projects March On
See More Vir Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vir Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vir Biotechnology and other key companies, straight to your email.

About Vir Biotechnology

Vir Biotechnology (NASDAQ:VIR), an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

View Vir Biotechnology Profile

More Earnings Resources from MarketBeat